IMAP India is pleased to have successfully advised Uquifa Sciences SLU on raising €33 million in structured debt from a renowned Singapore-based Asian credit fund. The funds have been utilized to repay legacy debt from Spanish banks, enabling Uquifa to optimize its capital structure and position itself for a renewed phase of growth.
Uquifa Sciences Group is backed by a global private equity fund in partnership with an Indian pharmaceutical company. With a heritage of over 85 years, Uquifa is a leading Contract Development and Manufacturing Organization (CDMO) specializing in small-molecule API development and manufacturing. The company operates FDA-approved facilities across Spain, Mexico, and Hungary, and serves a diversified global base of innovator and generic pharmaceutical clients.
The transaction reflects a strategic shift in Uquifa’s financing approach, transitioning from traditional domestic bank borrowings to a more flexible and growth-oriented international capital structure. IMAP India worked closely with the company’s leadership and stakeholders to structure, position, and execute the deal with an institutional lender aligned with Uquifa’s long-term business strategy.
The transaction is a testament to IMAP India’s capabilities in cross-border structured debt advisory, particularly for clients in the global pharmaceutical and life sciences sector.
